Cargando…

Duloxetine treatment adherence across mental health and chronic pain conditions

PURPOSE: This study applied a uniform methodology for measuring and comparing duloxetine adherence in the treatment of multiple chronic medical conditions. MATERIALS AND METHODS: Study patients 18–64 years of age initiating duloxetine therapy during 2008 were identified from a large managed care dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Able, Stephen L, Cui, Zhanglin, Shen, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930481/
https://www.ncbi.nlm.nih.gov/pubmed/24596469
http://dx.doi.org/10.2147/CEOR.S52950
_version_ 1782304529699569664
author Able, Stephen L
Cui, Zhanglin
Shen, Wei
author_facet Able, Stephen L
Cui, Zhanglin
Shen, Wei
author_sort Able, Stephen L
collection PubMed
description PURPOSE: This study applied a uniform methodology for measuring and comparing duloxetine adherence in the treatment of multiple chronic medical conditions. MATERIALS AND METHODS: Study patients 18–64 years of age initiating duloxetine therapy during 2008 were identified from a large managed care database. The study was restricted to patients with continuous health plan eligibility for 12 months pre- and post-duloxetine initiation. Study patients had ≥1 medical claim with an inpatient or outpatient diagnosis of one (and only one) of the following conditions: major depressive disorder (MDD); generalized anxiety disorder (GAD); fibromyalgia, diabetic peripheral neuropathic pain; or chronic musculoskeletal pain, as established in studies in patients with osteoarthritis and chronic lower back pain (CLBP). Patients initiating duloxetine who had two or more of the six studied conditions were not included in this study, thereby avoiding the need to differentiate between primary and secondary diagnoses from the claims records. Adherence rate was defined as the percentage of patients with a 365-day medication possession ratio ≥0.8. RESULTS: A total of 20,490 patients initiated duloxetine treatment during 2008 with a diagnosis of one of the studied conditions during the study period. The adherence rate in our sample was 34.6% and was highest among patients with MDD (37.3%) and lowest for patients with CLBP (29.9%). In general, adherence among patients with MDD and GAD was greater than among those with a chronic pain condition. CONCLUSION: Adherence among newly initiated duloxetine patients varied modestly across the medical conditions for which it was used. After adjusting for potential confounders, differences between the mental conditions (MDD and GAD) and the chronic pain conditions (CLBP, osteoarthritis, and diabetic peripheral neuropathic pain) were statistically significant. These results may be useful in the determination of expectations of adherence, and how it may differ for each of the conditions studied.
format Online
Article
Text
id pubmed-3930481
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-39304812014-03-04 Duloxetine treatment adherence across mental health and chronic pain conditions Able, Stephen L Cui, Zhanglin Shen, Wei Clinicoecon Outcomes Res Original Research PURPOSE: This study applied a uniform methodology for measuring and comparing duloxetine adherence in the treatment of multiple chronic medical conditions. MATERIALS AND METHODS: Study patients 18–64 years of age initiating duloxetine therapy during 2008 were identified from a large managed care database. The study was restricted to patients with continuous health plan eligibility for 12 months pre- and post-duloxetine initiation. Study patients had ≥1 medical claim with an inpatient or outpatient diagnosis of one (and only one) of the following conditions: major depressive disorder (MDD); generalized anxiety disorder (GAD); fibromyalgia, diabetic peripheral neuropathic pain; or chronic musculoskeletal pain, as established in studies in patients with osteoarthritis and chronic lower back pain (CLBP). Patients initiating duloxetine who had two or more of the six studied conditions were not included in this study, thereby avoiding the need to differentiate between primary and secondary diagnoses from the claims records. Adherence rate was defined as the percentage of patients with a 365-day medication possession ratio ≥0.8. RESULTS: A total of 20,490 patients initiated duloxetine treatment during 2008 with a diagnosis of one of the studied conditions during the study period. The adherence rate in our sample was 34.6% and was highest among patients with MDD (37.3%) and lowest for patients with CLBP (29.9%). In general, adherence among patients with MDD and GAD was greater than among those with a chronic pain condition. CONCLUSION: Adherence among newly initiated duloxetine patients varied modestly across the medical conditions for which it was used. After adjusting for potential confounders, differences between the mental conditions (MDD and GAD) and the chronic pain conditions (CLBP, osteoarthritis, and diabetic peripheral neuropathic pain) were statistically significant. These results may be useful in the determination of expectations of adherence, and how it may differ for each of the conditions studied. Dove Medical Press 2014-02-11 /pmc/articles/PMC3930481/ /pubmed/24596469 http://dx.doi.org/10.2147/CEOR.S52950 Text en © 2014 Able et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Able, Stephen L
Cui, Zhanglin
Shen, Wei
Duloxetine treatment adherence across mental health and chronic pain conditions
title Duloxetine treatment adherence across mental health and chronic pain conditions
title_full Duloxetine treatment adherence across mental health and chronic pain conditions
title_fullStr Duloxetine treatment adherence across mental health and chronic pain conditions
title_full_unstemmed Duloxetine treatment adherence across mental health and chronic pain conditions
title_short Duloxetine treatment adherence across mental health and chronic pain conditions
title_sort duloxetine treatment adherence across mental health and chronic pain conditions
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930481/
https://www.ncbi.nlm.nih.gov/pubmed/24596469
http://dx.doi.org/10.2147/CEOR.S52950
work_keys_str_mv AT ablestephenl duloxetinetreatmentadherenceacrossmentalhealthandchronicpainconditions
AT cuizhanglin duloxetinetreatmentadherenceacrossmentalhealthandchronicpainconditions
AT shenwei duloxetinetreatmentadherenceacrossmentalhealthandchronicpainconditions